Format

Send to

Choose Destination
See comment in PubMed Commons below
Zhongguo Fei Ai Za Zhi. 2013 Dec;16(12):663-70. doi: 10.3779/j.issn.1009-3419.2013.12.09.

[Clinical significance of ROS1 rearrangements in non-small cell lung cancer].

[Article in Chinese]

Author information

  • 1Cell Signaling Technology China Branch, Shanghai 200120, China.

Abstract

in English, Chinese

Chromosomal rearrangements involving the ROS1 receptor tyrosine kinase gene have recently been described in multiple malignancies, including non-small cell lung cancer (NSCLC). ROS1 rearrangement defines a new molecular subset of NSCLC with the prevalence of ROS1 rearrangements around 1%-2%. ROS1-positive NSCLCs arise in young never-smokers with adenocarcinoma that are similar to those observed in patients with ALK-rearranged NSCLC. Crizotinib demonstrates in vitro activity and early clinical trial shows marked antitumor activity in ROS1-rearranged patients. The overall response rate is around 56% and the disease control rate at 8 weeks is about 76%. Further understanding the ROS1 fusions in the pathogenesis of NSCLC, methods to detect ROS1 rearrangements, and targeting ROS1-rearranged NSCLC patients with specific kinase inhibitors would lead to an era of personalized medicine.

[PubMed - indexed for MEDLINE]
Free full text
PubMed Commons home

PubMed Commons

0 comments
How to join PubMed Commons

    Supplemental Content

    Full text links

    Icon for Editorial Office of Chinese Journal of Lung Cancer
    Loading ...
    Write to the Help Desk